Comparative Pharmacology

Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE 0 8 AND DEXTROSE 5 IN PLASTIC CONTAINER versus ZYNRELEF KIT.

Peer-Reviewed Evidence

Differential Analysis

LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER vs ZYNRELEF KIT

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER

Local Anesthetic / Antiarrhythmic (Class Ib)

Category A/B

ZYNRELEF KIT

Local Anesthetic and NSAID Combination

Category C

Head-to-Head

Clinical Matrix

Mechanism of Action

Lidocaine is an amide-type local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion channels, thereby blocking the initiation and conduction of nerve impulses. It also has antiarrhythmic properties by decreasing automaticity in Purkinje fibers and suppressing ventricular arrhythmias.

Zynrelef is a fixed-dose combination of bupivacaine and meloxicam. Bupivacaine blocks sodium channels in neuronal membranes, inhibiting nerve impulse conduction. Meloxicam inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis and inflammation.

Clinical Dosing

Intrathecal administration for spinal anesthesia: 50-100 mg (1.5-2 mL of 5% solution) as a single dose. For continuous epidural or peripheral nerve block, 0.8% solution with dextrose 5% is not typically used; refer to 1-2% lidocaine without dextrose for continuous infusion.

Instillation into the surgical site: 20 mL (300 mg bupivacaine and 9.3 mg meloxicam) as a single dose.

Direct Interaction

None Documented